To bring the most valuable candidate drugs or therapies to clinical trials, Creative Biolabs offers customized toxicological studies including carcinogenicity as a critical evaluation biomarker to assess the safety risks caused by immunotherapies. With extensive cancer expertise, and advanced capabilities, Creative Biolabs designs and conducts carcinogenic studies as well as data management until final reports are delivered.
Pharmaceuticals and biopharmaceuticals intended for long-term therapeutic use (such as continuous or intermittent administration of six months or longer), require carcinogenicity testing according to regulatory guidelines. In most cases, mouse or rat animal models will be used to assess the development of neoplastic lesions in multiple organs and organ systems. Creative Biolabs has earned a global reputation for excellence in the conduct of pre-clinical study design, animal model development, and rodent carcinogenicity projects. Given the high cost of carcinogenicity testing, long study duration, and large number of animals involved, Creative Biolabs is a trusted and reliable partner who can deliver flawless execution and is experienced in potential tumorigenic assessment and relevant human risk.
We work closely with safety assessment teams in Creative Biolabs to conduct carcinogenic studies with comprehensive endpoints, resulting in most appropriate solutions to our clients’ needs.
To help you make smarter decision in your drug and therapy discovery and development, we are empowered with large comprehensive historical control databases for carcinogenic studies, rasH2 mouse model, comprehensive evaluation of endpoints and cancers as well as other discipline expertise. At Creative Biolabs, you will benefit from a variety of GLP compliant toxicological studies. Please contact us for more information and a detailed quote.
For Research Use Only | Not For Clinical Use
Download our brochure